Nature reports how “[i]n the hunt for drugs that target diseases in the developing world, … [p]harmaceutical companies are making entire libraries of chemical compounds publicly available, allowing researchers to rifle through them for promising drug candidates.” The journal writes, “The latest push for open innovation, unveiled last month as part of a World Health Organization road map to control neglected tropical diseases, will see 11 companies sharing their intellectual property to give researchers around the world a head start on investigating drug leads.”
The Guardian’s “Poverty Matters Blog” examines how the government of Benin “is making headway in attempts to reduce deaths from malaria” by cracking down on counterfeit treatments, offering malaria treatment free-of-charge in public clinics and hospitals, and creating “an army of ordinary citizens in the battle against preventable diseases like malaria.” The article describes a UNICEF-supported program that trains and employs local residents as community health extension workers, who often serve as the front line in providing treatment for malaria or maternal and child health care (Smith, 2/10).
In this post in the Center for Global Development’s (CGD) “Global Health Policy” blog, Victoria Fan, a research fellow at the Center for Global Development (CGD), and Felix Lam, a malaria research analyst, examine the discrepancies between the WHO’s estimated number of malaria deaths worldwide and the data recently released by the Institute for Health Metrics and Evaluation (IHME). They ask, “Given the 1.2 billion dollars by donors to malaria in 2010, is it unreasonable to demand to know with more certainty, how many people are dying from malaria?” and go on to describe how each group analyzed data to get to their conclusions (2/9).
“To tackle neglected tropical diseases (NTDs), we need a far more collaborative and flexible approach,” Mark Booth, acting deputy director of Durham University’s Wolfson Research Institute and head of the N8 Parasitology Group, writes in this New Statesman opinion piece. Booth references the publication of new malaria mortality estimates in the Lancet and the signing of the so-called “London Declaration on NTDs” by a consortium of public and private partners last week and writes, “Malaria is not classified as an NTD because relatively large amounts of attention and funding have been pitted against the parasite. But if we now have to rethink malaria control strategies, then how confident can we be about controlling or eradicating any of the 17 NTDs identified by the World Health Organization?”
In this post in the Guardian’s “The Observer,” Mark Honigsbaum, a research associate at the University of Zurich’s Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague FranÃ§ois LÃ©vesque “have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the” sweet wormwood plant from which it is extracted. Honigsbaum notes that “extracting artemisinin is expensive and because it takes time to cultivate the plant there are often bottlenecks in supply,” and writes, “Their discovery has the potential to make the drug more affordable for the 225 million people affected by malaria every year” (2/4).
In this post in TIME World’s “Global Spin” blog, TIME’s Africa bureau chief Alex Perry examines questions surrounding an Institute for Health Metrics and Evaluation (IHME) study published in the Lancet on Friday that suggests “malaria kills almost twice as many people a year as previously believed,” writing, “If correct, at a stroke that overturns medical consensus, makes a nonsense of decades of World Health Organization (WHO) statistics — the official malaria numbers — and plunges the current multibillion-dollars anti-malaria campaign, and the push to reach a 2015 deadline for achieving the eight Millennium Development Goals, into grave doubt.”
The WHO has disputed a study published last week in the Lancet “that claims nearly twice as many people are dying of malaria than current estimates,” VOA News reports. The WHO “says both its estimates of malaria deaths and those of the Lancet study are statistically the same for all groups in all regions,” with one exception, VOA writes, noting, “WHO spokesman Gregory Hartl says there’s a notable statistical difference in regard to children over five and adults in Africa.”
“Malaria is killing more people worldwide than previously thought, but the number of deaths has fallen rapidly as efforts to combat the disease have ramped up, according to new research from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington” published in the Lancet on Thursday, an IHME press release reports. “More than 1.2 million people died from malaria worldwide in 2010, nearly twice the number found in the most recent comprehensive study of the disease,” the press release states (2/2). The study, funded by the Bill & Melinda Gates Foundation, “used new data and new computer modeling to build a historical database for malaria between 1980 and 2010,” BBC News notes (Bowdler, 2/2).
In this Global Health and Diplomacy opinion piece, Tanzanian President Jakaya Mrisho Kikwete examines efforts to meet Millennium Development Goal (MDG) targets on maternal and child mortality in Africa, noting, “Although Africa has just 12 percent of the global population, it accounts for half of all maternal deaths and half the deaths of children under five.” He writes, “Though global maternal deaths are in decline and women’s health has at last become a global priority, our goal of reducing maternal mortality by 75 percent in 2015 is still a long way off. … It is unacceptable to allow mothers and children to die when we have the knowledge and resources to save them.”
The Guardian examines the future of the Global Fund to Fight AIDS, Tuberculosis and Malaria as it enters its second decade, writing, “Despite its staggering successes — including helping put 3.3 million people on AIDS treatment, 8.6 million on anti-tuberculosis treatment and providing 230 million insecticide-treated nets for the prevention of malaria — the fund’s recent troubles had threatened to overshadow its accomplishments as it prepared to mark a decade as the world’s main financier of programs to fight these three global epidemics.” The news service highlights a $750 million pledge to the Fund by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, discusses recent managerial changes within the Fund, and quotes a number of experts about future challenges (Kelly, 2/2).